Net debt/EBITDA společnosti Navidea Biopharmaceuticals Inc
Jaká je hodnota metriky Net debt/EBITDA společnosti Navidea Biopharmaceuticals Inc?
Hodnota metriky Net debt/EBITDA společnosti Navidea Biopharmaceuticals Inc je 0.38
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na NYSEMKT ve srovnání se společností Navidea Biopharmaceuticals Inc
Čemu se věnuje společnost Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Firmy s metrikou net debt/ebitda podobnou společnosti Navidea Biopharmaceuticals Inc
- Hodnota metriky Net debt/EBITDA společnosti Kühne + Nagel International AG je 0.37
- Hodnota metriky Net debt/EBITDA společnosti Enphase je 0.38
- Hodnota metriky Net debt/EBITDA společnosti Global Technologies je 0.38
- Hodnota metriky Net debt/EBITDA společnosti RoodMicrotec N.V je 0.38
- Hodnota metriky Net debt/EBITDA společnosti VentriPoint Diagnostics je 0.38
- Hodnota metriky Net debt/EBITDA společnosti AM Resources je 0.38
- Hodnota metriky Net debt/EBITDA společnosti Navidea Biopharmaceuticals Inc je 0.38
- Hodnota metriky Net debt/EBITDA společnosti Caledonia Investments Plc je 0.38
- Hodnota metriky Net debt/EBITDA společnosti Tymlez je 0.38
- Hodnota metriky Net debt/EBITDA společnosti Synovus je 0.39
- Hodnota metriky Net debt/EBITDA společnosti Eskay Mining je 0.39
- Hodnota metriky Net debt/EBITDA společnosti Foxconn Interconnect Technology je 0.39
- Hodnota metriky Net debt/EBITDA společnosti DermTech je 0.39